| Symbol | FBIOP |
|---|---|
| Name | FORTRESS BIOTECH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1111 KANE CONCOURSE,SUITE 301, BAY HARBOR ISLANDS, Florida, 33154, United States |
| Telephone | +1 781 - 652-4500 |
| Fax | — |
| — | |
| Website | https://www.fortressbiotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001429260 |
| Description | Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Additional info from NASDAQ: |
Journey Medical Corporation to Participate inA.G.P.’s Annual Virtual Healthcare Conference
Read moreFortress Biotech to Participate in A.G.P.’sAnnual Virtual Healthcare Conference
Read moreFortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
Read moreNew Form SCHEDULE 13G/A - Fortress Biotech, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0000919574-26-003180 <b>Size:</b> 9 KB
Read more(99% Neutral) FORTRESS BIOTECH, INC. (FBIO) Reports Q2 2026 Financial Results
Read moreFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Read moreFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Read moreJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Read moreJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
Read moreFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
Read more